MiRNA-Processing Gene Methylation and Cancer Risk

Overview

Journal Cancer Epidemiol Biomarkers Prev

Specialties Biochemistry
Oncology
Public Health

Date 2018 Feb 25

PMID 29475968

Citations 12

Authors

Brian T Joyce

Yinan Zheng

Zhou Zhang

Lei Liu

Masha Kocherginsky

Robert Murphy

Chad J Achenbach

Jonah Musa

Firas Wehbe

Allan Just

Jincheng Shen

Pantel Vokonas

Joel Schwartz

Andrea A Baccarelli

Lifang Hou

Affiliations

Soon will be listed here.

Abstract

Dysregulation of miRNA and methylation levels are epigenetic hallmarks of cancer, potentially linked via miRNA-processing genes. Studies have found genetic alterations to miRNA-processing genes in cancer cells and human population studies. Our objective was to prospectively examine changes in DNA methylation of miRNA-processing genes and their associations with cancer risk. We examined cohort data from the Department of Veterans' Affairs Normative Aging Study. Participants were assessed every 3 to 5 years starting in 1999 through 2013 including questionnaires, medical record review, and blood collection. Blood from 686 consenting participants was analyzed using the Illumina 450K BeadChip array to measure methylation at CpG sites throughout the genome. We selected 19 genes based on a literature review, with 519 corresponding CpG sites. We then used Cox proportional hazards models to examine associations with cancer incidence, and generalized estimating equations to examine associations with cancer prevalence. Associations at false discovery rate < 0.05 were considered statistically significant. Methylation of three CpGs (: cg23230564, : cg06751583, and : cg21034183) was prospectively associated with time to cancer development (positively for cg06751583, inversely for cg23230564 and cg21034183), whereas methylation of one CpG site (: cg16131300) was positively associated with cancer prevalence. DNA methylation of , a key miRNA-processing gene, and may play a role in early carcinogenesis. Changes in miRNA processing may exert multiple effects on cancer development, including protecting against it via altered global miRNAs, and may be a useful early detection biomarker of cancer. .

Citing Articles

The role of DNA methylation and DNA methyltransferases (DNMTs) as potential biomarker and therapeutic target in non-small cell lung cancer (NSCLC).

Mohd Kamal K, Ghazali A, Ab Mutalib N, Abu N, Chua E, Masre S Heliyon. 2024; 10(19):e38663.

PMID: 39403460 PMC: 11472108. DOI: 10.1016/j.heliyon.2024.e38663.

Crosstalk between miRNAs and DNA Methylation in Cancer.

Saviana M, Le P, Micalo L, Del Valle-Morales D, Romano G, Acunzo M Genes (Basel). 2023; 14(5).

PMID: 37239435 PMC: 10217889. DOI: 10.3390/genes14051075.

MicroRNAs and long non-coding RNAs in cartilage homeostasis and osteoarthritis.

Gu J, Rao W, Huo S, Fan T, Qiu M, Zhu H Front Cell Dev Biol. 2022; 10:1092776.

PMID: 36582467 PMC: 9793335. DOI: 10.3389/fcell.2022.1092776.

Endothelin-3 is epigenetically silenced in endometrioid endometrial cancer.

Zmarzly N, Januszyk S, Mieszczanski P, Morawiec E, Buda P, Dziobek K J Cancer Res Clin Oncol. 2022; 149(9):5687-5696.

PMID: 36542159 PMC: 10356642. DOI: 10.1007/s00432-022-04525-w.

Stem-Cell Theory of Cancer: Implications for Antiaging and Anticancer Strategies.

Tu S, Pisters L Cancers (Basel). 2022; 14(5).

PMID: 35267646 PMC: 8909197. DOI: 10.3390/cancers14051338.

References

Hansen K, Timp W, Corrada Bravo H, Sabunciyan S, Langmead B, McDonald O . Increased methylation variation in epigenetic domains across cancer types. Nat Genet. 2011; 43(8):768-75. PMC: 3145050. DOI: 10.1038/ng.865. View

Rupp L, Brady B, Carpenter A, De Obaldia M, Bhandoola A, Bosselut R . The microRNA biogenesis machinery modulates lineage commitment during αβ T cell development. J Immunol. 2014; 193(8):4032-42. PMC: 4185242. DOI: 10.4049/jimmunol.1401359. View

Catto J, Miah S, Owen H, Bryant H, Myers K, Dudziec E . Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 2009; 69(21):8472-81. PMC: 2871298. DOI: 10.1158/0008-5472.CAN-09-0744. View

Brennan K, Flanagan J . Is there a link between genome-wide hypomethylation in blood and cancer risk?. Cancer Prev Res (Phila). 2012; 5(12):1345-57. DOI: 10.1158/1940-6207.CAPR-12-0316. View

Joshi A, Struhl K . Eaf3 chromodomain interaction with methylated H3-K36 links histone deacetylation to Pol II elongation. Mol Cell. 2005; 20(6):971-8. DOI: 10.1016/j.molcel.2005.11.021. View

Keogh M, Kurdistani S, Morris S, Ahn S, Podolny V, Collins S . Cotranscriptional set2 methylation of histone H3 lysine 36 recruits a repressive Rpd3 complex. Cell. 2005; 123(4):593-605. DOI: 10.1016/j.cell.2005.10.025. View

Leaderer D, Hoffman A, Zheng T, Fu A, Weidhaas J, Paranjape T . Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. Int J Mol Epidemiol Genet. 2011; 2(1):9-18. PMC: 3077234. View

Carrozza M, Li B, Florens L, Suganuma T, Swanson S, Lee K . Histone H3 methylation by Set2 directs deacetylation of coding regions by Rpd3S to suppress spurious intragenic transcription. Cell. 2005; 123(4):581-92. DOI: 10.1016/j.cell.2005.10.023. View

Campion J, Milagro F, Goyenechea E, Martinez J . TNF-alpha promoter methylation as a predictive biomarker for weight-loss response. Obesity (Silver Spring). 2009; 17(6):1293-7. DOI: 10.1038/oby.2008.679. View

10.

Diaz-Garcia C, Agudo-Lopez A, Perez C, Lopez-Martin J, Rodriguez-Peralto J, de Castro J . DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification. Carcinogenesis. 2013; 34(5):1031-8. DOI: 10.1093/carcin/bgt022. View

11.

Khan S, Greco D, Michailidou K, Milne R, Muranen T, Heikkinen T . MicroRNA related polymorphisms and breast cancer risk. PLoS One. 2014; 9(11):e109973. PMC: 4229095. DOI: 10.1371/journal.pone.0109973. View

12.

Pu X, Roth J, Hildebrandt M, Ye Y, Wei H, Minna J . MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients. Cancer Res. 2013; 73(6):1867-75. PMC: 3602350. DOI: 10.1158/0008-5472.CAN-12-0873. View

13.

Chiang H, Schoenfeld L, Ruby J, Auyeung V, Spies N, Baek D . Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. Genes Dev. 2010; 24(10):992-1009. PMC: 2867214. DOI: 10.1101/gad.1884710. View

14.

Liu H, Wang B, Han C . Meta-analysis of genome-wide and replication association studies on prostate cancer. Prostate. 2010; 71(2):209-24. DOI: 10.1002/pros.21235. View

15.

Laird P . Cancer epigenetics. Hum Mol Genet. 2005; 14 Spec No 1:R65-76. DOI: 10.1093/hmg/ddi113. View

16.

Joyce B, Gao T, Liu L, Zheng Y, Liu S, Zhang W . Longitudinal Study of DNA Methylation of Inflammatory Genes and Cancer Risk. Cancer Epidemiol Biomarkers Prev. 2015; 24(10):1531-8. PMC: 4592468. DOI: 10.1158/1055-9965.EPI-15-0198. View

17.

Teschendorff A, Jones A, Fiegl H, Sargent A, Zhuang J, Kitchener H . Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med. 2012; 4(3):24. PMC: 3446274. DOI: 10.1186/gm323. View

18.

Chong M, Rasmussen J, Rudensky A, Rundensky A, Littman D . The RNAseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease. J Exp Med. 2008; 205(9):2005-17. PMC: 2526196. DOI: 10.1084/jem.20081219. View

19.

Wilson A, Power B, Molloy P . DNA hypomethylation and human diseases. Biochim Biophys Acta. 2006; 1775(1):138-62. DOI: 10.1016/j.bbcan.2006.08.007. View

20.

Kitagawa N, Ojima H, Shirakihara T, Shimizu H, Kokubu A, Urushidate T . Downregulation of the microRNA biogenesis components and its association with poor prognosis in hepatocellular carcinoma. Cancer Sci. 2013; 104(5):543-51. PMC: 7657122. DOI: 10.1111/cas.12126. View